Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Par Pharmaceutical Companies has reported revenues of $234.44m for the third quarter ended 30 September 2010, compared to $294.8m for the same period in 2009.
Subscribe to our email newsletter
Par Pharma has posted a net income of $30.53m for the third quarter 2010, compared to $26.34m for the comparable period in 2009.
Operating income was $40.61m, compared to $42.38m for the comparable period in 2009.
Par Pharma has posted arevenue of $781.85m for the nine months ended 30 September 2010, compared to $902.84m for the year ago period.
For the nine months ended 30 September 2010, Par Pharma has posted a net income of $75.23m, compared to $66.23m for the year ago period.
Operating income was $108.1m, compared to $105.87m for the year ago period.
Par Pharma, through its wholly-owned subsidiary’s two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals, manufactures, develops and markets generic drugs and niche proprietary pharmaceuticals.